Test Table

Instand-NGS4P Partnering Platform_20210525-test

Company NameCountryPROVIDING solution for Lot No.SEEKING solution for Lot No.Short description of your proposed solutionShort description of your partnering needsContact PersonEMailPresentation and/or recording
AIT Austrian Institute of Technology GmbHAustriaLot 1(Targeted) DNA methylation sequencing, short NAs, exosomes, preanalytics, Library prepTarget enrichment companies, sequencing solution providersChrista Noehammerchrista.noehammer@ait.ac.at
Bahia SoftwareSpainLot 4Lots 1,2,3,4Bahia Software has significant experience developing software platforms for hospitals and research organizations. Bahia Software has proprietary platform technologies for Tumour Boards and is currently working in an R&D project to faciltate reporting to health professionals from Liquid Biopsy analysis. Bahia Software may also contribute with its accumulated knowledge and experience in PCP projects at european level. We have leaded and succesfully participated in two european PCP calls, very similar to InstandNGS4P.No specific partnering needs. Very open to collaborate with organizations more interested in Lots 1, 2 and 3Sergio Gomezsergio.figueiras@bahiasoftware.es
BC PlatformsSwedenLot 4Modular Genomic Data management and -Analysis solution for automation of Genomic data production from Raw data to actionable report. Integration of various secondary analysis pipelines, QC and variant interpretation/reporting tools from partners.Partners for secondary analysis, QC, variant interpretation and actionable reporting are welcomed. BC Platforms provide the ovarall workflow from raw data to these integrated reports in a CE-IVDR solution established on the market. Open for customization and integration to our modular offering.Henrik Plym-Forshellhenrik.plym-forshell@bcplatforms.com
DNVNorwayLot 4Risk mitigation and quality assuranceLooking to partner with providers of analysis software, reagents, sequencers etc. to ensure pipelines, computing infrastructure etc. is implemented safely and responsibly.Courtney Nadeaucourtney.david.nadeau@dnv.com
EuformaticsFinlandLot 3Clinical NGS variant interpretation and quality control softwareSecondary analysis, kit providers, sequencer manufacturersTommi Kaasalainentommi.kaasalainen@euformatics.com
fragmentiX Storage Solutions GmbHAustriaLot 3Trusted data environment by using SECRET SHARING with fragmentiX CLUSTER appliancesLooking for partners, resellers, customersWerner Strasserws@fragmentix.com
Geneyx Genomex LtdIsraelLot 3An AI-driven platform enables accurate analysis and interpretation of Whole Genome Sequencing (WGS) data. Produces rapid diagnosis at the highest diagnostics yields: >65%. Automated Phenotype – Genotype association – connecting disease symptoms to causal genes. The impact: Faster and better clinical diagnosis and distilling novel findings for targeted and personalized therapeutics.We may want to partner with more clinical genetic databasesRaviv ITZHAKYraviv@geneyx.com
Genuity ScienceIrelandLot 1,2,3,4Lot 1,2,3,4Genuity Science is a CAP accredited genomics facility and has  proven competencies in a range of capabilities including sample handling and processing (blood, saliva, tissue and tissue blocks) for genomic WGS analysis. Our organisation has automated and semi-automated bioinformatic pipelines for generation of a variety of reports. We have an end to end integrated genomic lab service delivery platform.We are seeking partners potentially in the area of pre-analytics and library prep and also in the area of integrated reporting. We have the ability and desire to partner across all lots. We have a strong sample handling, NGS and bioinformatic delivery platform already established but would be keen to partner up to bring innovation not only to the project but also into our facility through collaboration. The area of least development for us is around the clinical decision support.David Kavanaghdavid.kavanagh@genuitysci.com
HTG Molecular DiagnosticsGermanyLot 1,2,4Extraction-free Transcriptome and RNA-Panel Library Prep and Data Analysis SolutionWe are interested in partnering with Lot 2 and Lot 4 providers and also with QC control providers in Lot1. Looking forward to a great partnership!Selina Gaertnersgaertner@htgmolecular.com
iCellate MedicalSwedenLot 4End-to–end cancer NGS solution with strict adherence to clinical guidelines in ISO15189 accredited laboratory based on innovative sample types and analysesUniversity clinic with cancer patient management ready to merge Multidisciplinary Cancer Conference (MCC) with Molecular Tumor Board (MTB) to provide integrated management decision supportChrister Ericssonchrister.ericsson@icellate.se
Integrated DNA TechnologiesGermanyLot 1Lot 1We offer highly innovative solutions for NGS library preparation (DNA/RNA) of challenging clinical samples, targeted enrichment (hybridization capture and amplicon sequencing) and normalization. We are also partnering with suppliers for extraction of nucleic acids and automation.We are looking for providers of products in areas: pre-analytics (collection, storage and transport of specimen), QC of nucleic acids (assessment of amount, purity, integrity, fragment size distribution of NA and tumor content), QC of library prepped DNA (quantification and size distribution) and reference materials.K. Julia Dudakduda@idtdna.com
LGC SeracareGermanyLot 1Multiplexed biosynthetic reference materials in gDNA/RNA, FFPE and ctDNA format, including custom solutions and imuno-oncologyWe would like to partner with a provider of nucleic acid extraction, library prep and target enrichment solutions requiring reference materials for analytical validation and CE-IVD readiness of the platform.Krystyna Nahlikkrystyna.nahlik@lgcgroup.com
Maxeler TechnologiesUKLot 3,4Fast and efficient processing of sequencing data, explainable AI for drug selection, integrated in secure data analysis and collaboration platform.Partners in Lot 3 & 4 that are in need for accelerated sequence alignment algorithms, improved AI-based decision making for drug selection, or a platform for secure data sharing, analysis and dashboarding.Tobias Beckertbecker@maxeler.com
MicronomaUSALot 4Microbiome Aware Liquid BiopsyWe would like to partner with company specialized in reporting results to patients and clinicians.Sandrine Miller-Montgomerysandrine.miller@micronoma.com
Molecular HealthGermanyLot 4MH Guide is a NGS platform independent interpretation solution of NGS data.Thomas Holtrupthomas.holtrup@molecularhealth.com
Molecular HealthGermanyLot 4MH Guide quickly and accurately identifies and interprets genetic variants in tumors. The MH Guide report helps treatment providers choose therapy options and clinical trials that match the cancer patients molecular profile. MH Guide is an IVD medical device approved in the EU.Katrin Steckerkatrin.stecker@molecularhealth.com
Oncompass MedicineHungaryLot 4Multiparameter-based digital drug-assignment for treatment planning in precision oncology.Partnering preferred with an ESCAT- or other single biomarker-based reporting solution, which represents the standard-of-care in reporting. This could be complemented with the innovative multiparametric digital solution of Oncompass Medicine.Barbara Vodicska on behalf of Istvan Petakbarbara.vodicska@oncompassmedicine.com
RocheGermanyLot 4Robert BulteROBERT.BULTE@ROCHE.COM
Roche DiagnosticsGermanyLot 4Navify Mutation Profiler – a clinical decision support toolseamless integration of decision support tools & molecular tumor boards in a routine diagnostic processGerrit Schrammgerrit.schramm@roche.com
Semmelweis UniversityHungaryLot 4Miklos Garamimiklos.garami@gmail.com
University Medical Center GroningenThe NetherlandsLot 4not a solution provider, but end userAcademic partner for validation of tools for variant interpretation and reporting, and interaction between MTBsLeon van Kempenl.van.kempen@umcg.nl